VIKING THERAPEUTICS
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK0612, a first-in-class, orally available drug candidate type 2 diabetes. The Company’s second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia. Viking is also developing three novel preclinical programs targeted at metabolic diseases and anemia.
VIKING THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Founded:
2012-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.vikingtherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(858) 550-7810
Total Funding:
1.06 B USD
Technology used in webpage:
Domain Not Resolving Google Maps HSTS IPv6 Cloudflare Hosting Cloudflare CDN Cloudflare Microsoft Cloudflare Bot Manager Cloudflare SSL
Similar Organizations
Aardvark Therapeutics
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Ardelyx
Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.
Bone Health Technologies
Bone Health Technologies is developing a new standard of care for treating both osteoporosis and osteopenia, the precursor to osteoporosis.
Boulder Care
Boulder is a telehealth provider of treatment and long-term support for people with substance use disorders
C4 Therapeutics
C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Faeth Therapeutics
Faeth Therapeutics is a cancer metabolism company that focuses on nutrition treatments for cancer patients.
IVX Health
IVX Health is a provider of infusion and injection therapy for those with complex chronic conditions.
Kaia Health
Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of medical disorders.
SPR Therapeutics
SPR Therapeutics is a medical device company.
Current Employees Featured
Michel Moreau CFO @ Viking Therapeutics
CFO
Brian Lian CEO & President @ Viking Therapeutics
CEO & President
2013-01-01
Founder
Stock Details
Investors List
Aspire Capital Partners LLC
Aspire Capital Partners LLC investment in Post-IPO Equity - Viking Therapeutics
Ligand Pharmaceuticals
Ligand Pharmaceuticals investment in Debt Financing - Viking Therapeutics
Official Site Inspections
http://www.vikingtherapeutics.com Semrush global rank: 605.5 K Semrush visits lastest month: 53.15 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Viking Therapeutics"
Viking Therapeutics - Viking Therapeutics
Overview Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and …See details»
Viking Therapeutics - Overview
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.See details»
Management - Viking Therapeutics
Management Brian Lian, Ph.D. President and Chief Executive Officer Dr. Lian serves as our President and Chief Executive Officer, and as a director. Prior to founding Viking Therapeutics, …See details»
Viking Therapeutics - Crunchbase Company Profile
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.See details»
Viking Therapeutics, Inc. - LinkedIn
Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders. Our most advanced ...See details»
Viking Therapeutics, Inc. - Company Profile
Viking Therapeutics is a biopharmaceutical company developing novel therapeutics for metabolic and endocrine disorders, with a focus on NASH/MASH, obesity, and X-ALD.See details»
Viking Therapeutics
Feb 21, 2025 Viking Therapeutics, Inc., began in 2013 when two experienced pharmaceutical scientists joined forces with experienced venture capitalists, biotechnology executives, and …See details»
Viking Therapeutics Company Profile | Management and
Find contact information for Viking Therapeutics. Learn about their Research & Development, Business Services market share, competitors, and Viking Therapeutics's email format.See details»
Viking Therapeutics InvestorRoom - Corporate …
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.See details»
Viking Therapeutics, Inc. (LON: 0VQA) Company Profile
Jan 17, 2025 Company profile for Viking Therapeutics, Inc. (LON: 0VQA) with a description, list of executives, contact details and other key facts.See details»
Board of Directors - Viking Therapeutics
Board of Directors Lawson Macartney, DVM, Ph.D.; Chairman Dr. Macartney has served as the Chairperson of our Board since May 2015 and as a member of our Board since May 2014. …See details»
Viking Therapeutics - Craft
Oct 29, 2024 Viking Therapeutics has 5 employees at their 1 location. See insights on Viking Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Viking Therapeutics - Management
President and Chief Executive Officer Dr. Lian serves as our President and Chief Executive Officer, and as a director. Prior to joining Viking Therapeutics, he was a Managing Director …See details»
Viking Therapeutics CEO and Key Executive Team - Craft.co
Viking Therapeutics's President, Chief Executive Officer, Director is Brian Lian. Other executives include Geoffrey Barker, Senior Vice President, Pharmaceutical Development; Marianne …See details»
Viking Therapeutics Announces Completion of Enrollment in …
15 hours ago Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with ObesitySee details»
Viking Therapeutics Signs Broad Manufacturing Agreement With ...
SAN DIEGO, March 11, 2025 / PRNewswire / -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel …See details»
Who Owns Viking Therapeutics – CANVAS, SWOT, PESTEL & BCG …
Dec 19, 2024 These stakeholders play a crucial role in shaping the company's future and influencing its strategic decisions, making it essential to have a clear picture of who holds the …See details»
Viking Therapeutics Announces Completion of Enrollment in …
4 hours ago 13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking …See details»
Viking Therapeutics, Inc. | Insights
Nov 19, 2024 This year has posed substantial challenges for global markets: a prolonged period of high interest rates, ongoing geopolitical instability, democratic uncertainty, and an …See details»
VK2735 - Viking Therapeutics
VK2735 (Subcutaneous & Oral Formulations)Dual GLP-1/GIP Receptor Agonist Obesity and Metabolic Disorders Overview & Profile We are developing a unique series of novel dual …See details»